MedTrace Logo

Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients

NCT05642793 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-12-14

No results posted yet for this study

Summary

This is an unmasking randomized clinical trial. the main purpose of this study is to analyze whether posvitrectomy proactive use of conbercept can reduce the rate of postoperative complication in PDR patients.

Conditions

  • Proliferative Diabetic Retinopathy

Interventions

DRUG

proactive Anti-VEGF (conbercept) use

preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.

DRUG

passive Anti-VEGF (conbercept) use

No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Huijin Chen, Dr. · Peking University Third Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2023-09-30
Completion
2024-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05642793 on ClinicalTrials.gov